The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
Open accessAbstract
Functional precision medicine is a strategy whereby live tumor cells from affected individuals are directly perturbed with drugs to provide immediately translatable, personalized information to guide therapy. The heterogeneity of human cancer has led to the realization that personalized approaches are needed to improve treatment outcomes. Precision oncology has traditionally used static features of the tumor to dictate which therapies should be used. Static features can include expression of key targets or genomic analysis of mutations to identify therapeutically targetable "drivers." Although a surprisingly small proportion of individuals derive clinical benefit from the static approach, functional precision medicine can provide additional information regarding tumor vulnerabilities. We discuss emerging technologies for functional precision medicine as well as limitations and challenges in using these assays in the clinical trials that will be necessary to determine whether functional precision medicine can improve outcomes and eventually become a standard tool in clinical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
Self-citationCancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935
Modelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
Self-citationPrecision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Self-citationHerland, A., Maoz, B. M., Das, D., Somayaji, M. R., Prantil-Baun, R., Novak, R., Cronce, M., Huffstater, T., Jeanty, S. S. F., Ingram, M., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0498-9 · Cited by 500
Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., Landis, M. D., Wiechmann, L., Schiff, R., Giuliano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4081 · Cited by 481
Hassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467
Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C.-H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00337-6 · Cited by 416
Self-citationDrug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citationFunctional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Self-citationVo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Self-citationTumor organoids: Opportunities and challenges to guide precision medicine
Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339
Majumder, B., Baraneedharan, U., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M., Brijwani, N., Pinto, D. D., Prasath, A., Shanthappa, B. U., et al. (2015) · Nature Communications · doi:10.1038/ncomms7169 · Cited by 308
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
Self-citationFlaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03010 · Cited by 294
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0094 · Cited by 262
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine
Dijkstra, K. K., Monkhorst, K., Schipper, L. J., Hartemink, K. J., Smit, E. F., Kaing, S., de Groot, R., Wolkers, M. C., Clevers, H., Cuppen, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107588 · Cited by 254
Garrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
A microengineered pathophysiological model of early-stage breast cancer
Choi, Y., Hyun, E., Seo, J., Blundell, C., Kim, H. C., Lee, E., Lee, S. H., Moon, A., Moon, W. K., & Huh, D. (2015) · Lab on a Chip · doi:10.1039/c5lc00514k · Cited by 222
Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., & Somerfield, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.065 · Cited by 208
Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0538 · Cited by 206
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0410 · Cited by 193
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Self-citationDormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Vallette, F. M., Olivier, C., Lézot, F., Oliver, L., Cochonneau, D., Lalier, L., Cartron, P.-F., & Heymann, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.004 · Cited by 190
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R. M., Vrbanac, L., Richardson, A. B., Kobayashi, H., Price, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0073 · Cited by 185
Snijder, B., Vladimer, G. I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., Lopez de la Fuente, O., Choi, H.-S., van der Kouwe, E., Gültekin, S., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30208-9 · Cited by 177
3D Tumor Models and Their Use for the Testing of Immunotherapies
Boucherit, N., Gorvel, L., & Olive, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603640 · Cited by 171
Némati, F., Sastre-Garau, X., Laurent, C., Couturier, J., Mariani, P., Desjardins, L., Piperno-Neumann, S., Lantz, O., Asselain, B., Plancher, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3066 · Cited by 165
The National Lung Matrix Trial of personalized therapy in lung cancer
Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O'Rourke, N., Brewster, A. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2481-8 · Cited by 157
Tumor slice culture system to assess drug response of primary breast cancer
Naipal, K. A. T., Verkaik, N. S., Sánchez, H., van Deurzen, C. H. M., den Bakker, M. A., Hoeijmakers, J. H. J., Kanaar, R., Vreeswijk, M. P. G., Jager, A., & van Gent, D. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2119-2 · Cited by 156
Patient-derived organoid (PDO) platforms to facilitate clinical decision making
Liu, L., Yu, L., Li, Z., Li, W., & Huang, W. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02677-2 · Cited by 152
Palmer, A. C., Chidley, C., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.50036 · Cited by 145
Irmisch, A., Bonilla, X., Chevrier, S., Lehmann, K.-V., Singer, F., Toussaint, N. C., Esposito, C., Mena, J., Milani, E. S., Casanova, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.004 · Cited by 142
Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D., Samson, D. J., Holt, L., Zelman, D., & Ajani, J. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0354 · Cited by 139
Barrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Wheeler, D. A., Takebe, N., Hinoue, T., Hoadley, K. A., Cardenas, M., Hamilton, A. M., Laird, P. W., Wang, L., Johnson, A., Dewal, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.015 · Cited by 106
A pan-cancer organoid platform for precision medicine
Larsen, B. M., Kannan, M., Langer, L. F., Leibowitz, B. D., Bentaieb, A., Cancino, A., Dolgalev, I., Drummond, B. E., Dry, J. R., Ho, C.-S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109429 · Cited by 105
Engineering approaches for studying immune-tumor cell interactions and immunotherapy
Shelton, S. E., Nguyen, H. T., Barbie, D. A., & Kamm, R. D. (2021) · iScience · doi:10.1016/j.isci.2020.101985 · Cited by 93
A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
Klinghoffer, R. A., Bahrami, S.-B., Hatton, B. A., Frazier, J. P., Moreno‐Gonzalez, A., Strand, A. D., Kerwin, W. S., Casalini, J. R., Thirstrup, D. J., You, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7489 · Cited by 90
Multiplexed drug testing of tumor slices using a microfluidic platform
Horowitz, L. F., Rodriguez, A. D., Dereli-Korkut, Z., Lin, R., Castro, K., Mikheev, A. M., Monnat, R. J., Folch, A., & Rostomily, R. C. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0117-y · Cited by 88
Ayuso, J. M., Gong, M. M., Skala, M. C., Harari, P. M., & Beebe, D. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201900925 · Cited by 73
du Manoir, S., Orsetti, B., Bras-Gonçalves, R., Nguyen, T.-T., Lasorsa, L., Boissière‐Michot, F., Massemin, B., Colombo, P., Bibeau, F., Jacot, W., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.010 · Cited by 69
Bhola, P. D., Ahmed, E., Guerriero, J. L., Sicińska, E., Su, E., Lavrova, E., Ni, J., Chipashvili, O., Hagan, T., Pioso, M. S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aay1451 · Cited by 68
Self-citationGendoo, D. M. A., Denroche, R. E., Zhang, A. X. W., Radulovich, N., Jang, G. H., Lemire, M., Fischer, S. E., Chadwick, D. E., Lungu, I. M., Ibrahimov, E., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006596 · Cited by 57
Chen, A. P., Kummar, S., Moore, N., Rubinstein, L., Zhao, Y., Williams, P. M., Palmisano, A., Sims, D., Coyne, G. O., Rosenberger, C. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00372 · Cited by 53
Lalazar, G., Requena, D., Ramos-Espiritu, L. S., Ng, D., Bhola, P. D., de Jong, Y. P., Wang, R., Narayan, N. J. C., Shebl, B., Levin, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0872 · Cited by 49
Self-citationToward improved in vitro models of human cancer
Ayuso, J. M., Park, K.-Y., Virumbrales-Muñoz, M., & Beebe, D. J. (2021) · APL Bioengineering · doi:10.1063/5.0026857 · Cited by 40
Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts
Byrne, A. T., Alférez, D., Amant, F. C., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budínská, E., Caldas, C., Chang, D. K.-F., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.85 · Cited by 37
Gao, B., Huang, C., Kernstine, K. H., Pelekanou, V., Kluger, Y., Jiang, T., Peters‐Hall, J. R., Coquelin, M. L., Girard, L., Zhang, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14366 · Cited by 26
Yu, F., Lu, Y., Tao, L., Jiang, Y., Lin, D., Wang, L., Petersson, F., Yoshiyama, H., Koeffler, H. P., Goh, B.-C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17628-z · Cited by 25
Garcia, J. S., Bhatt, S., Fell, G. G., Sperling, A. S., Burgess, M. W., Keshishian, H., Yilma, B., Brunner, A. M., Neuberg, D. S., Carr, S. A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25692 · Cited by 22
Self-citationGuillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.28.433268 · Cited by 17
Self-citationKleine, W. (1986) · Gynecologic Oncology · doi:10.1016/0090-8258(86)90066-1 · Cited by 14
Toward improved models of human cancer
Welm, B. E., Vaklavas, C., & Welm, A. L. (2021) · APL Bioengineering · doi:10.1063/5.0030534 · Cited by 10
Self-citationNCI-MATCH Sets “Benchmark of Actionability”
(2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2020-100 · Cited by 7
Cited by
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 315
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses
Ramos Zapatero, M., Tong, A., Opzoomer, J. W., O’Sullivan, R., Cardoso Rodriguez, F., Sufi, J., Vlckova, P., Nattress, C., Qin, X., Claus, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.005 · Cited by 72
Plattner, C., Lamberti, G., Blattmann, P., Kirchmair, A., Rieder, D., Loncova, Z., Sturm, G., Scheidl, S., Ijsselsteijn, M., Fotakis, G., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108399 · Cited by 27
Metadata
- Authors
- Letai, A., Bhola, P., & Welm, A. L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 40
- Issue
- 1
- Pages
- 26-35
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4200579603
- Cited by
- 281
- References
- 68
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.